Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta‐analysis

2021 ◽  
Author(s):  
Hongxia Gong ◽  
Yun Su ◽  
Lixia Zhao ◽  
Li Ma ◽  
Liying Zhang ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Gastroesophageal Junction ◽  
Targeted Drugs ◽  
Efficacy And Safety ◽  
Gastroesophageal Junction Cancer

scholarly journals The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Hongqiong Yang ◽  
Yaojun Zhou ◽  
Liangzhi Wang ◽  
Tianyi Gu ◽  
Mengjia Lv ◽  
...  
Keyword(s):  
Response Rate ◽  
Meta Analysis ◽  
Gastroesophageal Junction ◽  
Objective Response ◽  
Progression Free Survival ◽  
Pooled Analysis ◽  
First Line ◽  
Free Survival ◽  
Gastroesophageal Junction Cancer ◽  
Line Chemotherapy

Five electronic databases were searched for eligible records. Outcomes were presented and analyzed according to the objective response rate (ORR), progression-free survival (PFS) rate, and overall survival (OS) rate. Five records involving 2,024 participants were included in the study. The pooled analysis of OS and PFS were longer with ramucirumab (RAM) therapy than without RAM for OS (odds ratio OR = 0.90 , 95% confidence interval CI = 0.82 – 1.00 , p = 0.05 ) and PFS ( OR = 0.74 , 95 % CI = 0.57 – 0.96 , p = 0.02 ). Moreover, compared with the current first-line chemotherapy, the OS ( OR = 0.93 , 95 % CI = 0.83 – 1.04 , p = 0.19 ) and PFS ( OR = 0.82 , 95 % CI = 0.64 – 1.06 , p = 0.13 ) results were not significantly higher with RAM. The ORRs of the patients in the RAM therapy groups were significantly higher than those in the groups without RAM ( OR = 1.40 , 95 % CI = 1.14 – 1.73 , p = 0.001 ).

scholarly journals Transthoracic Resection versus Non-Transthoracic Resection for Gastroesophageal Junction Cancer: A Meta-Analysis

PLoS ONE ◽  
2012 ◽  
Vol 7 (6) ◽  
pp. e37698 ◽  
Author(s):  
Kun Yang ◽  
Hai-Ning Chen ◽  
Xin-Zu Chen ◽  
Qing-Chun Lu ◽  
Lin Pan ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Gastroesophageal Junction ◽  
Gastroesophageal Junction Cancer

Comparison of Platinum/S-1 and Platinum/5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis Based on Randomized Controlled Trials

Chemotherapy ◽  
2020 ◽  
Vol 65 (1-2) ◽  
pp. 11-20 ◽  
Author(s):  
Dongyi Luo ◽  
Li Wang ◽  
Xinling Chen ◽  
Yiting Xiong ◽  
Fengming Yi ◽  
...  
Keyword(s):  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Gastroesophageal Junction ◽  
Objective Response ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Time To Failure ◽  
First Line ◽  
Randomized Controlled ◽  
Gastroesophageal Junction Cancer

Background: Platinum/S-1 (PS) and platinum/5-fluorouracil (PF) as first-line chemotherapies are extensively used for the treatment of advanced gastric or gastroesophageal junction cancer (AGC); however, there is no definite consensus on which regimen is best. In our meta-analysis, we compared PS with PF in terms of their efficacy and safety in AGC patients. Methods: PubMed, ScienceDirect, Web of Science, Scopus, Ovid MEDLINE, EMBASE, The Cochrane Library, Google Scholar, and CNKI were systematically searched for pertinent literature. We analyzed overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse effects (AEs) as major end points. Results: A total of 3,225 studies were identified, among which 6 randomized controlled trials, including 1,736 participants, were ultimately included in our analysis. Our results showed that PS and PF were comparable in terms of OS (p = 0.33, 95% confidence interval [CI]: 0.84–1.06), PFS (p = 0.63, 95% CI: 0.87–1.09), ORR (p = 0.38, 95% CI: 0.91–1.28), DCR (p = 0.41, 95% CI: 0.86–1.43), total AEs (p = 0.41, 95% CI: 0.98–1.01), and grade ≥3 AEs (p = 0.58, 95% CI: 0.82–1.41). However, those who received PF had a shorter time to failure (TTF) (p = 0.01, 95% CI: 0.77–0.97), and a significantly higher rate and more severe cases of stomatitis, nausea, and hypokalemia were reported in the PF group. Conclusions: PF and PS show similar antitumor efficacy (OS, PFS, ORR, and DCR), but patients receiving PS exhibit longer TTF and fewer AEs (stomatitis, nausea, and hypokalemia) than those receiving PF.

Sign in / Sign up

Export Citation Format

Share Document